A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

2020320 citationsJournal Articlebronze Open Access

Authors

Sandip Pravin Patel

Megan Othus

Young Kwang Chae · Northwestern University

Francis J. Giles · Midwestern University

Donna E. Hansel

Preet Paul Singh

Annette Campbell Fontaine

Abstract

Ipilimumab plus nivolumab demonstrated a 44% ORR in patients with nonpancreatic high-grade neuroendocrine carcinoma, with 0% ORR in low/intermediate grade disease.

Topics & Keywords

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Neuroblastoma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 26, Issue 10, pp. 2290-2296

DOI: 10.1158/1078-0432.ccr-19-3356

Field-Weighted Citation Impact: 32.73